Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Pfizer begins Phase II trial of PF-06252616 to treat duchenne muscular dystrophy Pfizer has started patient enrollment in a multicenter Phase II clinical trial of PF-06252616, an experimental, infused, anti-myostatin monoclonal antibody, to treat Duchenne muscular dystrophy (DMD). Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Pfizer reports positive results from phase III trial of Pregabalin
Pfizer announced top-line results from a double-blind Phase III study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN).
News
GlaxoSmithKline reports positive results from Phase III trial of shingles candidate vaccine
By PBR Staff Writer
GlaxoSmithKline (GSK) has reported positive results from a Phase III trial designed to evaluate the efficacy of HZ/su, an investigational vaccine for the prevention of shingles.
News

Contract Research

KCR buys Ukrainian CRO AXIS’ project portfolio
By PBR Staff Writer
KCR, European Contract Research Organization (CRO), has purchased the whole portfolio of clinical projects from the Ukrainian CRO, AXIS Group.
News
CannaPharmaRx, PharmaDirections to start research & discovery program in Cannabinoid Science
CannaPharmaRx, the New Jersey-based pharmaceutical company, will be working with PharmaDirections, a pharmaceutical project management and consulting group, as it launches its R&D platform to investigate product opportunities in endocannabinoid science for ultimate commercialization in global markets.
News

Contract Services

Valeant Canada secures rights of hypertension drugs Edarbi and Edarbyclor from Takeda
By PBR Staff Writer
Valeant Canada has acquired the Canadian rights to Edarbi (azilsartan medoxomil) and Edarbyclor (azilsartan medoxomil and chlorthalidone) from Takeda Pharmaceutical International.
News
Lightlake enters into license agreement with Adapt Pharma Operations
Lightlake Therapeutics, a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced that it has entered into a license agreement with Adapt Pharma Operations, a wholly owned subsidiary of Adapt Pharma Limited, an Ireland-based pharmaceutical company.
News